Thera-SAbDab

MIROMAVIMAB

> Structural Summary

Therapeutic	Miromavimab
Target	Rabies Virus Strain ERA GP Ectodomain Epitope G-II
Heavy Chain	QVQLQQPGSVLVRPGASVKLSCKTSGYAFTSSWMHWAKQRPGQGLEWIGQTHPNSGYTNYNEKFKGKATLTVDTSSSTAYVDLSSLTSEDSAVYYCARESGDGPHWYFDVWGAGTAVTVSS
Light Chain	DIVMTQSHKFMSTSVGDRVSITCKASQDVSTAVAWYQQKPGQSPKLLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQQHYSSPHTFGGGTKLETK
100% seqID Fv Structure	None
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

There are currently no PDB structures close in sequence to this therapeutic Fv. Click here to build a model with ABodyBuilder.

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb (Mouse)
Isotype	G1
Highest Clinical Trial (June '19)	Unknown
Estimated Status (June '19)	Active
Recorded Developmental Technology	na
INN Year Proposed	2019
INN Year Recommended	None
Companies Involved	Candila Healthcare
Conditions Approved	na
Conditions Active	Rabies post-exposure
Conditions Discontinued	na
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]